{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:24:39Z","timestamp":1791109479876,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":4796,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Clinical Nutrition"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.3945\/ajcn.2009.28449d","type":"journal-article","created":{"date-parts":[[2009,11,19]],"date-time":"2009-11-19T03:16:36Z","timestamp":1258600596000},"page":"262S-266S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Peroxisome proliferator-activated receptor translational research and clinical experience"],"prefix":"10.1016","volume":"91","author":[{"given":"Wayman Wendell","family":"Cheatham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3945\/ajcn.2009.28449D_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2165\/00003495-198836030-00004","article-title":"Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia","volume":"36","author":"Todd","year":"1988","journal-title":"Drugs"},{"key":"10.3945\/ajcn.2009.28449D_bib2","doi-asserted-by":"crossref","first-page":"30221","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor g (PPARg)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"10.3945\/ajcn.2009.28449D_bib3","unstructured":"Dieken ML, Federwisch M, De Meyts P. Relationships between the structure of insulin and its physiological effects. In: Federwisch M, Dieken M, DeMeyts P, eds. Insulin and related proteins: structure to function and pharmacology. Dordrecht, Netherlands: Springer, 2004: 121\u201330."},{"key":"10.3945\/ajcn.2009.28449D_bib4","unstructured":"Flakoll PJ, Jensen MD, Cherrington AD. Physiologic action of insulin. In: LeRoith D, Olefsky J, Taylor S, eds. Diabetes mellitus, a fundamental clinical text. Philadelphia, PA: Lippincott, Williams and Wilkins, 2004:65\u2013182."},{"key":"10.3945\/ajcn.2009.28449D_bib5","first-page":"139","article-title":"Insulin secretagogues: old and new","volume":"7","author":"Lebovitz","year":"1999","journal-title":"Diabetes Res"},{"key":"10.3945\/ajcn.2009.28449D_bib6","first-page":"4047","article-title":"The importance of beta cell failure in the development and progression of type 2 diabetes","volume":"86","author":"Kahn","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3945\/ajcn.2009.28449D_bib7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI7231","article-title":"The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus","volume":"104","author":"Weyer","year":"1999","journal-title":"J Clin Invest"},{"key":"10.3945\/ajcn.2009.28449D_bib8","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.2337\/diabetes.50.2007.S160","article-title":"Beta cell dysfunction and failure in type 2 diabetes: potential mechanisms","volume":"50","author":"Porte","year":"2001","journal-title":"Diabetes"},{"key":"10.3945\/ajcn.2009.28449D_bib9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2337\/diacare.15.7.815","article-title":"Onset of NIDDM occurs at least 4\u20137 years before clinical diagnosis","volume":"15","author":"Harris","year":"1992","journal-title":"Diabetes Care"},{"key":"10.3945\/ajcn.2009.28449D_bib10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/diacare.13.6.610","article-title":"Glucose toxicity","volume":"13","author":"Rossetti","year":"1990","journal-title":"Diabetes Care"},{"key":"10.3945\/ajcn.2009.28449D_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1074\/jbc.M200958200","article-title":"Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle","volume":"277","author":"Yu","year":"2002","journal-title":"J Biol Chem"},{"key":"10.3945\/ajcn.2009.28449D_bib12","unstructured":"Hull RL, Kahn SE. Islet amyloid in type 2 diabetes. In: LeRoith D, Olefsky J, Taylor S, eds. Diabetes mellitus, a fundamental clinical text. Philadelphia, PA: Lippincott, Williams and Wilkins, 2004:151\u201364."},{"issue":"suppl 6A","key":"10.3945\/ajcn.2009.28449D_bib13","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0002-9343(02)01276-7","article-title":"Beta-cell dysfunction and insulin resistance in type-2 diabetes: role of metabolic and genetic abnormalities","volume":"113","author":"LeRoith","year":"2002","journal-title":"Am J Med"},{"key":"10.3945\/ajcn.2009.28449D_bib14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1210\/jcem-73-4-691","article-title":"Clinical review 26: insulin resistance in obese and nonobese man","volume":"73","author":"Caro","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3945\/ajcn.2009.28449D_bib15","unstructured":"Kelmendi M, Ylli A, Husi G. Insulin resistance among non-diabetic subjects with normal weight, overweight and obesity, Third World Congress on Insulin Resistance Syndrome. San Francisco, CA, November 2005. Tarzana, CA: Metabolic Endocrine Educational Foundation."},{"key":"10.3945\/ajcn.2009.28449D_bib16","first-page":"78","article-title":"Resistance to insulin-stimulated glucose uptake and hyperinsulinemia: role in non-insulin dependent diabetes mellitus, high blood pressure, dyslipedemia and coronary heart disease","volume":"17","author":"Reaven","year":"1991","journal-title":"Diabetes Metab"},{"key":"10.3945\/ajcn.2009.28449D_bib17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.RES.0000165803.47776.38","article-title":"Adipocyte signaling and lipid homeostasis: sequelae of insulin resistant adipose tissue","volume":"96","author":"Yu","year":"2005","journal-title":"Circ Res"},{"key":"10.3945\/ajcn.2009.28449D_bib18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11892-009-0006-9","article-title":"Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia","volume":"9","author":"Gutierrez","year":"2009","journal-title":"Curr Diab Rep"},{"key":"10.3945\/ajcn.2009.28449D_bib19","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.109.194506","article-title":"Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-\u00b1 expression","volume":"104","author":"Higuchi","year":"2009","journal-title":"Circ Res"},{"key":"10.3945\/ajcn.2009.28449D_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","article-title":"Oral antihyperglycemic therapy for type 2 diabetes: scientific review","volume":"287","author":"Inzucchi","year":"2002","journal-title":"JAMA"},{"key":"10.3945\/ajcn.2009.28449D_bib21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.3945\/ajcn.2009.28449D_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2337\/diab.46.3.433","article-title":"Cardiac and glycemic benefits of troglitazone treatment in NIDDM","volume":"46","author":"Ghazzi","year":"1997","journal-title":"Diabetes"},{"key":"10.3945\/ajcn.2009.28449D_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2125.1977.tb00761.x","article-title":"Effect of clofibrate on glucose tolerance in maturity onset diabetes","volume":"4","author":"Barnett","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"10.3945\/ajcn.2009.28449D_bib24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.58.4.5","article-title":"International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors","volume":"58","author":"Michalik","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.3945\/ajcn.2009.28449D_bib25","doi-asserted-by":"crossref","unstructured":"Maroo A, Tang WHW. Effects of thiazolidinediones on serum lipoproteins. In: Davidson M, Toth P, Maki K, eds. Therapeutic lipidology. Totowa, NJ: Humana Press, 2008:149\u201358.","DOI":"10.1007\/978-1-59745-533-6_8"},{"key":"10.3945\/ajcn.2009.28449D_bib26","unstructured":"Flakoll PJ, Jensen MD, Cherrington AD. Physiologic action of insulin. In: LeRoith D, Olefsky J, Taylor S, eds. Diabetes mellitus: a fundamental clinical text. Philadelphia, PA: Lippincott,Williams and Wilkins, 2004:165\u201382."},{"key":"10.3945\/ajcn.2009.28449D_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.3945\/ajcn.2009.28449D_bib28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2337\/diab.32.9.830","article-title":"Ciglitazone, a new hypoglycemic agent. I. Studies in ob\/ob and db\/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats","volume":"32","author":"Chang","year":"1983","journal-title":"Diabetes"},{"key":"10.3945\/ajcn.2009.28449D_bib29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/jpet.104.076950","article-title":"Ciglitazone-induced lenticular opacities in rats: in vivo and whole lens explant culture evaluation","volume":"312","author":"Aleo","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3945\/ajcn.2009.28449D_bib30","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/S0140-6736(00)04960-6","article-title":"Lessons from the glitazones: a story of drug development","volume":"357","author":"Gale","year":"2001","journal-title":"Lancet"},{"key":"10.3945\/ajcn.2009.28449D_bib31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2337\/diab.32.9.839","article-title":"Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL\/6J-ob\/ob and -+\/? mice","volume":"32","author":"Chang","year":"1983","journal-title":"Diabetes"},{"key":"10.3945\/ajcn.2009.28449D_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(02)01529-2","article-title":"Troglitazone-induced liver failure: a case study","volume":"114","author":"Graham","year":"2003","journal-title":"Am J Med"},{"key":"10.3945\/ajcn.2009.28449D_bib33","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation"},{"key":"10.3945\/ajcn.2009.28449D_bib34","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"10.3945\/ajcn.2009.28449D_bib35","unstructured":"Nesto R, Cannon CP, Gerstein HC, et al. Results of the APPROACH trial: assessment on the prevention of progression by rosiglitaxone on atherosclerosis in type 2 diabetes patients with cardiovascular history. Circulation 2008;118:2313 (abstr)."},{"key":"10.3945\/ajcn.2009.28449D_bib36","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/archinte.164.19.2097","article-title":"A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors","volume":"164","author":"Chiquette","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.3945\/ajcn.2009.28449D_bib37","unstructured":"Rosenstock J. for the pioglitazone HCL study group. Effects of pioglitazone on beta-cell function: HOMA bcf. Diabetologia 2000;43(suppl 1):A192 (abstr)."},{"key":"10.3945\/ajcn.2009.28449D_bib38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.3945\/ajcn.2009.28449D_bib39","unstructured":"Matthews D. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetologia 1999;42 (suppl 1):A858 (abstr)."},{"key":"10.3945\/ajcn.2009.28449D_bib40","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic \u03b2-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"key":"10.3945\/ajcn.2009.28449D_bib41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.3945\/ajcn.2009.28449D_bib42","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","year":"2006","journal-title":"Lancet"},{"key":"10.3945\/ajcn.2009.28449D_bib43","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2337\/diabetes.50.5.1021","article-title":"\u03b2-Cell mass dynamics in Zucker diabetic fatty rats","volume":"50","author":"Finegood","year":"2001","journal-title":"Diabetes"},{"key":"10.3945\/ajcn.2009.28449D_bib44","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.3945\/ajcn.2009.28449D_bib45","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3945\/ajcn.2009.28449D_bib46","first-page":"1065","article-title":"Safety issues and prospects for future generations of PPAR modulators","volume":"1771","author":"Rubenstrunk","year":"2007","journal-title":"Biochem Biophys Acta"},{"key":"10.3945\/ajcn.2009.28449D_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","article-title":"Long term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis","volume":"180","author":"Loke","year":"2009","journal-title":"CMAJ"},{"issue":"suppl","key":"10.3945\/ajcn.2009.28449D_bib48","doi-asserted-by":"crossref","first-page":"251S","DOI":"10.3945\/ajcn.2009.28449A","article-title":"From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor \u03b3 modulators","volume":"91","author":"Blackburn","year":"2010","journal-title":"Am J Clin Nutr"},{"issue":"suppl","key":"10.3945\/ajcn.2009.28449D_bib49","doi-asserted-by":"crossref","first-page":"254S","DOI":"10.3945\/ajcn.2009.28449B","article-title":"Fibroblast growth factor 21: from pharmacology to physiology","volume":"91","author":"Kliewer","year":"2010","journal-title":"Am J Clin Nutr"},{"issue":"suppl","key":"10.3945\/ajcn.2009.28449D_bib50","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.3945\/ajcn.2009.28449C","article-title":"Adiponectin in insulin resistance: lessons from translational research","volume":"91","author":"Ziemke","year":"2010","journal-title":"Am J Clin Nutr"},{"issue":"suppl","key":"10.3945\/ajcn.2009.28449D_bib51","doi-asserted-by":"crossref","first-page":"267S","DOI":"10.3945\/ajcn.2009.28449E","article-title":"Selective peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) modulation as a strategy for safer therapeutic PPAR\u03b3 activation","volume":"91","author":"Higgins","year":"2010","journal-title":"Am J Clin Nutr"}],"container-title":["The American Journal of Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002916523016222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002916523016222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ajcn\/article-pdf\/91\/1\/262S\/23862273\/262s.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:19:07Z","timestamp":1685467147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002916523016222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0002916523016222"],"URL":"https:\/\/doi.org\/10.3945\/ajcn.2009.28449d","relation":{},"ISSN":["0002-9165"],"issn-type":[{"value":"0002-9165","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peroxisome proliferator-activated receptor translational research and clinical experience","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3945\/ajcn.2009.28449D","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Society for Nutrition. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}